Unusual Insertion and Deletion at Codon 67 and 69 of HIV Type 1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment-Failing South Indian Patients: Association with Other Resistance Mutations
Restricted accessResearch articleFirst published online December, 2012
Unusual Insertion and Deletion at Codon 67 and 69 of HIV Type 1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment-Failing South Indian Patients: Association with Other Resistance Mutations
We report a high frequency of drug resistance mutations among patients with unusual insertions or deletions at the β3–β4 hairpin-loop-coding region of HIV-1 subtype C reverse transcriptase, during failure of first-line antiretroviral therapy containing only reverse transcriptase inhibitors in Chennai, India.
Get full access to this article
View all access options for this article.
References
1.
ThompsonMA, AbergJA, CahnP, MontanerJS, RizzardiniG, TelentiA, GatellJM, GünthardHF, HammerSM, HirschMS, JacobsenDM, ReissP, RichmanDD, VolberdingPA, YeniP, SchooleyRT. the International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA, 2010; 304,3:321–333.
2.
HirschMS, GünthardHF, SchapiroJM, Brun-VézinetF, ClotetB, HammerSM, JohnsonVA, KuritzkesDR, MellorsJW, PillayD, YeniPG, JacobsenDM, RichmanDD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis, 2008; 47,2:266–285.
3.
RambautA, PosadaD, CrandallKA, HolmesEC. The causes and consequences of HIV evolution. Nat Rev Genet, 2004; 5:52–61.
4.
HuigenMC, de GraafL, EgginkD, SchuurmanR, MüllerV, StampA, StammersDK, BoucherCA, NijhuisM. Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology, 2007; 364,2:395–406.
5.
Menéndez-AriasL, MatamorosT, Cases-González. Insertions and deletions in HIV-1 reverse transcriptase: Consequences for drug resistance and viral fitness. Curr Pharm Des, 2006; 12,15:1811–1825.
6.
SaravananS, VidyaM, BalakrishananPet al.Evaluation of two human imunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods, 2009; 159:211–216.
7.
JohnsonVA, Brun-VézinetF, ClotetB, GünthardHF, KuritzkesDR, PillayD, SchapiroJM, RichmanDD. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med, 2010; 18,5:156–163.
8.
LiuTF, ShaferRW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis, 2006; 42,11:1608–1618.
9.
RossL, ParkinN, ChappeyC, FisherR, St ClairM, BatesMet al.Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS, 2004; 18:1691–1696.
10.
ImamichiT, BergSC, ImamichiH, LopezJC, MetcalfJA, FalloonJ, LaneHC. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr to Gly) at codon 69. J Virol, 2000; 74:10958–10964.
11.
WintersMA, MeriganTC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother, 2001; 45:2276–2279.
12.
SarafianosSG, DasK, ClarkADJr, DingJ, BoyerPL, HughesSHet al.Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proc Natl Acad Sci USA, 1999; 96:10027–10032.
13.
DevalJ, WhiteKL, MillerMD, ParkinNT, CourcambeckJ, HalfonPet al.Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem, 2004; 279:509–516.
14.
ManosuthiW, ButlerDM, ChantratitaW, SukasemC, RichmanDD, SmithDM. Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. AIDS Res Hum Retroviruses, 2010; 26,6:609–611.
